Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Claps

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Future Oncology (London, England)|April 27, 2026
Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancerLudovica Cella, Alessio Finocchiaro, Aleksander Ślusarczyk, et al.
World Journal of Urology|July 1, 2021
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survivalFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
European Urology Oncology|May 5, 2021
Corrigendum to 'Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)' [European Urology Oncology 3 (2021) 256-263]Michele Marchioni, Maximilian Kriegmair, Mathias Heck, et al.
Cancers|October 16, 2025
Local Recurrence After Nephron Surgery: What to Do? An Italian Multicentric RegistryAngelo Porreca, Filippo Marino, Davide De Marchi, et al.
European Urology Oncology|January 1, 2021
Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)Michele Marchioni, Maximilian Kriegmair, Mathias Heck, et al.
Current Urology|April 21, 2025
COVID-19 outbreak impact on urolithiasis treatments: A multicenter retrospective study across 9 urological centers in ItalyGiorgio Mazzon, Stefania Ferretti, Emanuele Serafin, et al.
Minerva Urology and Nephrology|June 23, 2023
A survey on preferences, attitudes, and perspectives of Italian urology trainees: implications of the novel national residency matching programLuigi Napolitano, Martina Maggi, Gianluca Sampogna, et al.
World Journal of Urology|November 20, 2025
Is histological grade a useful parameter in muscle-invasive urothelial bladder cancer? Results from a multicenter study on the impact of different grading systems on disease-free survival after upfront radical cystectomyEmily Rinderknecht, Francesco Claps, Peter J Bostrom, et al.
Cancers|February 13, 2026
Survival Outcomes of BCG Only, BCG Plus EMDA-MMC or Upfront Radical Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A Multicentre, International, Collaborative Study from Tertiary Referral InstitutionsFrancesco Del Giudice, Valerio Santarelli, Amir Khan, et al.
Frontiers in Oncology|April 17, 2023
Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 ("Oligometastatic") and M2 ("Polymetastatic") subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC)Margaret F Meagher, Maria C Mir, Andrea Minervini, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Future Oncology (London, England)|April 27, 2026
Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancerLudovica Cella, Alessio Finocchiaro, Aleksander Ślusarczyk, et al.
World Journal of Urology|July 1, 2021
Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survivalFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
European Urology Oncology|May 5, 2021
Corrigendum to 'Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)' [European Urology Oncology 3 (2021) 256-263]Michele Marchioni, Maximilian Kriegmair, Mathias Heck, et al.
Cancers|October 16, 2025
Local Recurrence After Nephron Surgery: What to Do? An Italian Multicentric RegistryAngelo Porreca, Filippo Marino, Davide De Marchi, et al.
European Urology Oncology|January 1, 2021
Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)Michele Marchioni, Maximilian Kriegmair, Mathias Heck, et al.
Current Urology|April 21, 2025
COVID-19 outbreak impact on urolithiasis treatments: A multicenter retrospective study across 9 urological centers in ItalyGiorgio Mazzon, Stefania Ferretti, Emanuele Serafin, et al.
Minerva Urology and Nephrology|June 23, 2023
A survey on preferences, attitudes, and perspectives of Italian urology trainees: implications of the novel national residency matching programLuigi Napolitano, Martina Maggi, Gianluca Sampogna, et al.
World Journal of Urology|November 20, 2025
Is histological grade a useful parameter in muscle-invasive urothelial bladder cancer? Results from a multicenter study on the impact of different grading systems on disease-free survival after upfront radical cystectomyEmily Rinderknecht, Francesco Claps, Peter J Bostrom, et al.
Cancers|February 13, 2026
Survival Outcomes of BCG Only, BCG Plus EMDA-MMC or Upfront Radical Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A Multicentre, International, Collaborative Study from Tertiary Referral InstitutionsFrancesco Del Giudice, Valerio Santarelli, Amir Khan, et al.
Frontiers in Oncology|April 17, 2023
Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 ("Oligometastatic") and M2 ("Polymetastatic") subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC)Margaret F Meagher, Maria C Mir, Andrea Minervini, et al.
Pageof 10